No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Hvsen Biotechnology Co., Ltd. is a company based in Wuhan, China, that focuses on the global research, development, and manufacturing of macrolide active pharmaceutical ingredients (APIs) and finished drug products. The company's diverse product portfolio features tylvalosin, offered in both raw material form and various preparations, along with florfenicol preparations and a broader selection of other macrolide-based offerings. Additionally, Hvsen produces a range of veterinary pharmaceuticals, available as both raw ingredients and finished drugs, alongside traditional Chinese medicine extracts.
www.whhsyy.comNo one on the platform currently holds 300871.SZ.
No tracked institution reports a position in 300871.SZ as of their last filing.
No one on the platform has traded 300871.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 12.4% | — | — | — | ||
| Rev. Growth % | 40.1% | 16.7% | ||||
| Profit Margin % | 15.1% | 6.7% | 12.7% | |||
| Free Cash Flow Margin % | 8.4% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.8B | -14.9% | $1.75 | $1.75–$1.75 | — | 1 |
| 2027 | $2.2B | +19.6% | $1.92 | $1.92–$1.92 | — | 1 |
| 2028 | $2.6B | +21.1% | $2.48 | $2.48–$2.48 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 300871.SZHvsen Biotechnology Co., Ltd. | $21.73 | +1.92% | $4.4B | — |
| 002286.SZBaolingbao Biology Co.,Ltd. | $7.69 | +0.26% | $2.9B | — |
| 002868.SZLifecome Biochemistry Co.,Ltd. | $22.94 | +0.61% | $3.6B | — |
| 300858.SZBeijing Scitop Bio-tech Co., Ltd. | $14.25 | +3.11% | $3.8B | — |
| 300942.SZShenzhen Bioeasy Biotechnology Co., Ltd. | $6.24 | +1.46% | $2.5B | — |
| 603439.SSGuiZhou SanLi Pharmaceutical Co.,Ltd | $14.38 | +1.70% | $5.8B | — |
| 603566.SSPulike Biological Engineering, Inc. | $10.08 | -0.98% | $3.4B | — |
Source: Financial Modeling Prep · peers by sector/industry